Refine
Year of publication
Document Type
- Article (42)
- Conference Proceeding (3)
- Preprint (1)
Has Fulltext
- yes (46)
Is part of the Bibliography
- no (46) (remove)
Keywords
- ataxia telangiectasia (5)
- Ataxia telangiectasia (4)
- ATM (3)
- Ataxia-telangiectasia (3)
- asthma (3)
- lung function (3)
- primary immunodeficiency (3)
- Allergic asthma (2)
- Cytokines (2)
- Neurodegeneration (2)
- body plethysmography (2)
- cystic fibrosis (2)
- malignancy (2)
- Albumin ratio (1)
- Allergen immunotherapy (1)
- Allergic rhinitis (1)
- Allergoid (1)
- Aspergillus fumigatus (1)
- Ataxia score (1)
- Atm (1)
- Biomarker (1)
- Bronchial inflammation (1)
- CD23 (1)
- CD45RA naïve lymphocytes (1)
- CRP (1)
- CVID (1)
- Cell distribution (1)
- Cerebrospinal fluid (1)
- Cumulative dose (1)
- Curvilinear dose response (1)
- D-dimer (1)
- Disease progression (1)
- Double-blind placebo-controlled trial (1)
- Epidemiologie (1)
- Erregernachweis (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exercise challenge (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced asthma (1)
- Exercise-induced bronchoconstriction (1)
- Exhaled nitric oxide (1)
- F508del homozygous (1)
- Fever (1)
- Forced expiratory volume in 1 s (1)
- German PID-NET registry (1)
- Grass pollen (1)
- GvHD (1)
- HSCT (1)
- HbA1c (1)
- Healthcare worker (1)
- Hexavalent vaccine (1)
- House dust mite allergy (1)
- IgA deficiency (1)
- IgE (1)
- IgG substitution therapy (1)
- Immunodeficiency (1)
- Immunoglobulins (1)
- Induced sputum (1)
- LABAs (1)
- Labordiagnostik (1)
- Local IgE (1)
- Local allergic rhinitis (1)
- Longchain polyunsaturated fatty acids (1)
- Lymphopenia Mortality (1)
- Methacholine challenge test (1)
- Mortality (1)
- Neurofilament light chain (1)
- NfL (1)
- Non-allergic-rhinitis (1)
- OGTT (1)
- PID prevalence (1)
- Paracetamol (1)
- Pertussis (1)
- Pneumococcal conjugate vaccine (1)
- Prophylaxis (1)
- Respimat® Soft Mist™ Inhaler (1)
- Respiratorische Infekte (1)
- SARS-CoV-2 (1)
- Smart nebulizer (1)
- T-lymphocytes (1)
- TNF inhibitors (1)
- Ultrasonic nebulizer (1)
- Vaccine uptake rate (1)
- Viruspneumonien (1)
- acute lung injury (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- asthma phenotypes (1)
- ataxia score (1)
- autovaccine (1)
- basic mechanisms (1)
- bio imaging (1)
- biologics (1)
- bioluminescence (1)
- birch pollen allergoid (1)
- bronchial allergen challenge (1)
- bronchial allergen provocation (1)
- bronchiolitis obliterans syndrome (1)
- cancer surveillance (1)
- chronic inflammation (1)
- clinical immunology (1)
- combined immunodeficiency (1)
- cumulative dose (1)
- demonstration of the infectious agent (1)
- desensitization (1)
- device handling (1)
- diabetes (1)
- diabetes therapy (1)
- dose response curve (1)
- epidemiology (1)
- gap junction protein alpha 4-genotype (1)
- granulomas (1)
- granulomatous inflammation (1)
- haploidentical (1)
- healthcare worker (1)
- hepatic steatosis (1)
- hospitalization (1)
- house dust mite allergy (1)
- immune deficiency (1)
- immunologic (1)
- inflammation (1)
- inflammatory markers (1)
- inhalation flow profiles (1)
- inhaled steroids (1)
- laboratory diagnostic (1)
- ligelizumab (1)
- liver disease (1)
- long-acting β2-agonists (1)
- lung disease (1)
- lung disease phenotype (1)
- mesenchymal stromal/stem cells (1)
- miRNA (1)
- neurodegeneration (1)
- omalizumab (1)
- pertussis (1)
- phenotype/genotype relation (1)
- pollen allergy (1)
- postinfectious bronchiolitis obliterans (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- pre-school asthma (1)
- precision medicine (1)
- preschool asthma (1)
- preschool children (1)
- primary immunodeficiency (PID) (1)
- qRT-PCR (1)
- radio sensitivity (1)
- readmission rates (1)
- real-world evidence (1)
- registry for primary immunodeficiency (1)
- respiratory disease (1)
- respiratory failure (1)
- respiratory infections (1)
- safety (1)
- severe uncontrolled asthma (1)
- spirometry (1)
- stem cell transplantation (1)
- subcutaneous immunotherapy (1)
- sublingual immunotherapy (1)
- tailored treatment schedule (1)
- tiotropium (1)
- tolerability (1)
- tolerance (1)
- tracking (1)
- vaccine uptake rate (1)
- virus pneumonia (1)
Institute
Die Häufigkeitsrate atopischer Erkrankungen bei Kindern, wie Heuschnupfen, Asthma, Neurodermitis (atopische Dermatitis), nimmt weltweit zu. Die Gründe sind vielschichtig. Gesichert ist der Zusammenhang zwischen der erblichen Überempfindlichkeit gegenüber natürlichen Substanzen (Atopie) und vermehrter Allergen- und Passivrauch-Exposition sowie Zunahme der Ein-Kind-Familien, Veränderung der mikrobiologischen Besiedlung des Darmes und Infektexposition. Besonders gut untersucht wurden diese Zusammenhänge von Erika von Mutius in einer Studie, in der sie von 1991 bis 1992 die Häufigkeit von Asthma in München (5030 Kinder) und Leipzig/Bitterfeld (2623 Kinder) verglichen hat.
BACKGROUND: In two clinical trials, low-grade fever was observed more frequently after coadministration than after separate administration of two recommended routine pediatric vaccines. Since fever is an important issue with vaccine tolerability, we performed this open-label study on the efficacy and safety of prophylactic use of paracetamol (acetaminophen, Benuron(R)) in children administered routine 7-valent pneumococcal conjugate vaccine (PCV-7) coadministered with hexavalent vaccine (diphtheria-tetanus-acellular pertussis-hepatitis B, polio, Haemophilus influenzae type b vaccine [DTPa-HBV-IPV/Hib]) in Germany.
METHODS: Healthy infants (N = 301) who received a 3-dose infant series of PCV-7 and DTPa-HBV-IPV/Hib plus a toddler dose were randomly assigned 1:1 to prophylactic paracetamol (125 mg or 250 mg suppositories, based on body weight) at vaccination, and at 6--8 hour intervals thereafter, or a control group that received no paracetamol. Rectal temperature and local and other systemic reactions were measured for 4 days post vaccination; adverse events were collected throughout the study.
RESULTS: In the intent-to-treat population, paracetamol reduced the incidence of fever >=38[degree sign]C, but this reduction was only significant for the infant series, with computed efficacy of 43.0% (95% confidence interval [CI]: 17.4, 61.2), and not significant after the toddler dose (efficacy 15.9%; 95% CI: -19.9, 41.3); results were similar in the per protocol (PP) population. Fever >39[degree sign]C was rare during the infant series, such that there were too few cases for assessment. After the toddler dose, paracetamol effectively reduced fever >39[degree sign]C, reaching statistical significance in the PP population only (efficacy 79%; 95% CI: 3.9, 97.7). Paracetamol also reduced reactogenicity, but there were few significant differences between groups after any dose. No vaccine-related serious adverse events were reported.
CONCLUSIONS: Paracetamol effectively prevented fever and other reactions, mainly during the infant series. However, as events were generally mild and of no concern in either group our data support current recommendations to administer paracetamol to treat symptoms only and not for routine prophylaxis.Trial registration: NCT00294294.
Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia
(2014)
Background: Ataxia telangiectasia (A-T) is a rare but devastating and progressive disorder characterized by cerebellar dysfunction, lymphoreticular malignancies and recurrent sinopulmonary infections. In A-T, disease of the respiratory system causes significant morbidity and is a frequent cause of death.
Methods: We used a self-limited murine model of hydrochloric acid-induced acute lung injury (ALI) to determine the inflammatory answer due to mucosal injury in Atm (A-T mutated)- deficient mice (Atm−/−).
Results: ATM deficiency increased peak lung inflammation as demonstrated by bronchoalveolar lavage fluid (BALF) neutrophils and lymphocytes and increased levels of BALF pro-inflammatory cytokines (e.g. IL-6, TNF). Furthermore, bronchial epithelial damage after ALI was increased in Atm−/− mice. ATM deficiency increased airway resistance and tissue compliance before ALI was performed.
Conclusions: Together, these findings indicate that ATM plays a key role in inflammatory response after airway mucosal injury.
Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia and immunodeficiency. The neurological decline may be caused by multiple factors of which ongoing inflammation and oxidative stress may play a dominant role. The objective of the present investigation was to determine cerebrospinal fluid (CSF) proteins and possible low-grade inflammation and its relation to age and neurological deterioration. In the present study, we investigated 15 patients with A-T from 2 to 16 years. Our investigation included blood and CSF tests, clinical neurological examination, A-T score, and MRI findings. The albumin ratio (AR) was analyzed to determine the blood–brain-barrier function. In addition, inflammatory cytokines (IL-1α, IL-6, IL-8, IL-12 p40, IL-17A, IFN-γ, TNF-α) were measured by the multiplex cytometric bead array. We compared the results with those from an age-matched control group. Three of the A-T patients were analyzed separately (one after resection of a cerebral meningioma, one after radiation and chemotherapy due to leukemia, one after stem cell transplantation). Patient had significantly more moderate and severe side effects due to CSF puncture (vomiting, headache, need for anti-emetic drugs) compared with healthy controls. Total protein, albumin, and the AR increased with age indicating a disturbed blood barrier function in older children. There were no differences for cytokines in serum and CSF with the exception of IL-2, which was significantly higher in controls in serum. The AR is significantly altered in A-T patients, but low-grade inflammation is not detectable in serum and CSF.
Background: Both standard and low-dose allergen provocations are an established tool in asthma research to improve our understanding of the pathophysiological mechanism of allergic asthma. However, clinical symptoms are less likely to be induced. Therefore, we designed a protocol for repetitive high-dose bronchial allergen challenges to generate clinical symptoms and airway inflammation.
Methods: A total of 27 patients aged 18 to 40 years with positive skin-prick tests and mild asthma underwent repetitive high-dose allergen challenges with household dust mites for four consecutive days. Pulmonary function and exhaled NO were measured at every visit. Induced sputum was analysed before and after the allergen challenges for cell counts, ECP, IL-5, INF-γ, IL-8, and the transcription factor Foxp3.
Results: We found a significant decrease in pulmonary function, an increased use of salbutamol and the development of a late asthmatic response and bronchial hyperresponsiveness, as well as a significant induction of eNO, eosinophils, and Th-2 cytokines. Repeated provocation was feasible in the majority of patients. Two subjects had severe adverse events requiring prednisolone to cope with nocturnal asthma symptoms.
Conclusions: Repeated high-dose bronchial allergen challenges resulted in severe asthma symptoms and marked Th-2-mediated allergic airway inflammation. The high-dose challenge model is suitable only in an attenuated form in diseased volunteers for proof-of-concept studies and in clinical settings to reduce the risk of severe asthma exacerbations.
Trial registration: ClinicalTrials.govNCT00677209
A handling study to assess use of the Respimat(®) Soft Mist™ inhaler in children under 5 years old
(2015)
Background: Respimat® Soft Mist™ Inhaler (SMI) is a hand-held device that generates an aerosol with a high, fine-particle fraction, enabling efficient lung deposition. The study objective was to assess inhalation success among children using Respimat SMI, and the requirement for assistance by the parent/caregiver and/or a valved holding chamber (VHC).
Methods: This open-label study enrolled patients aged <5 years with respiratory disease and history of coughing and/or recurrent wheezing. Patients inhaled from the Respimat SMI (air only; no aerosol) using a stepwise configuration: “1” (dose released by child); “2” (dose released by parent/caregiver), and “3” (Respimat SMI with VHC, facemask, and parent/caregiver help). Co-primary endpoints included the ability to perform successful inhalation as assessed by the investigators using a standardized handling questionnaire and evaluation of the reasons for success. Inhalation profile in the successful handling configuration was verified with a pneumotachograph. Patient satisfaction and preferences were investigated in a questionnaire.
Results: Of the children aged 4 to <5 years (n=27) and 3 to <4 years (n=30), 55.6% and 30.0%, respectively, achieved success without a VHC or help; with assistance, another 29.6% and 10.0%, respectively, achieved success, and the remaining children were successful with VHC. All children aged 2 to <3 years (n=20) achieved success with the Respimat SMI and VHC. Of those aged <2 years (n=22), 95.5% had successful handling of the Respimat SMI with VHC and parent/caregiver help. Inhalation flow profiles generally confirmed the outcome of the handling assessment by the investigators. Most parent/caregiver and/or child respondents were satisfied with operation, instructions for use, handling, and ease of holding the Respimat SMI with or without a VHC.
Conclusions: The Respimat SMI is suitable for children aged <5 years; however, children aged <5 years are advised to add a VHC to complement its use.